Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study.
نویسندگان
چکیده
We conducted a post hoc pharmacoeconomic analysis of a multicenter, open-label, randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA reductase inhibitors-atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The 534 patients requiring cholesterol-lowering therapy took the drugs for 8 weeks with 15 different regimens. Low-density lipoprotein (LDL) was measured after 6 weeks of diet (baseline) and after 8 weeks of treatment with a study drug. At dosages of 10, 20, and 40 mg/day, atorvastatin was associated with significantly greater reductions in LDL than equivalent dosages of the other agents. Cost-effectiveness calculated as the annual acquisition cost/percentage LDL reduction was greatest with atorvastatin 10 mg ($17.96), fluvastatin 40 mg ($19.83), atorvastatin 20 mg ($22.85), and atorvastatin 40 mg ($24.96). All other dosages were above $25.00/year/percentage LDL reduction. Atorvastatin was the most cost-effective HMG-CoA reductase inhibitor. Fluvastatin 40 mg/day also had a favorable cost:effectiveness ratio but lowered LDL only by 23%.
منابع مشابه
The effect of aerobic training and consumption of L-carnitine supplements on HMG-CoA reductase and LDL receptor in the liver of male wistar rats toxicated by boldenone
Introduction: The aim of this study was to investigate the effect of aerobic training and consumption of L-carnitine supplements on HMG-CoA reductase and low density lipoprotein receptor (LDL-R) in the liver of male Wistar rats toxicated by boldenone. Materials and methods: In this clinical study, 30 male Wistar rats aged 12 weeks (weight 195±7.94g) were randomly divided into five groups: cont...
متن کاملPharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.
We evaluated the economic efficiency as well as the clinical effectiveness on serum lipid levels of a change in drug therapy from bezafibrate or a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor to fenofibrate. Subjects were 26 outpatients suffering from type IIb or type IV hyperlipidemia who visited our hospital between October 2000 and January 2001. Medication doses, and s...
متن کاملاثر حفاظتی سیمواستاتین در آسیب ناشی از ایسکمی – رپرفیوژن کلیه و نقش کانالهای پتاسیمی حساس به آدنوزین تری فسفات
Background & Aim: Renal dysfunction due to ischemia-reperfusion (I/R) injury is a common problem following renovascular surgery or kidney transplantation. There is a lot of emerging evidence that statins, which are HMG-COA reductase inhibitors, have renal protective effects against ischemia-reperfusion injury,but the exact mechanism of their protective effect has not been detected properly....
متن کاملHypolipidemic effects of total flavonoide extracted from the leaves of Actinidia kolomikta in rats fed a high-fat diet
Objective(s): This study was to investigate the antihyperlipidemic and antioxidant effect of total flavonoid extract from Actinidia kolomikta (TFAK) in hyperlipidemia induced by a high-fat diet. Materials and Methods: Male SD rats were randomly divided into 6 groups: normal group, model (hyperlipidemic diet) group, hyperlipedemic diet supplemented with TFAK (50, 100 and 200 mg/kg) and simvastat...
متن کاملComparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
OBJECTIVE To evaluate the comparative efficacy and safety of the 4 currently available hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, fluvastatin, lovastatin, pravastatin, and simvastatin, in the treatment of primary hypercholesterolemia. DATA SOURCES English-language clinical studies, abstracts, and review articles identified from MEDLINE searches and bibliographies of iden...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Pharmacotherapy
دوره 20 7 شماره
صفحات -
تاریخ انتشار 2000